In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
How to Find a Cancer Treatment Trial
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary
Featured Clinical Trials Supported by NCI

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 25 for your search:

Drug:  denileukin diftitox
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: #33, NCT00211198

Phase III Randomized, Double-Blind Study of Two Doses of the IL-2 Receptor-Targeted Cytotoxin DAB389-IL2 for Recurrent or Persistent Cutaneous T-Cell Lymphoma (Summary Last Modified 02/96)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SERAGEN-93-04-10, NCI-V95-0738

Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: Other
Protocol IDs: ERLANGEN-ONTAK, EU-20246, NCT00056134

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6308, NCI-2010-00800, 127, UWCC-6308, UWCC-05-6951-A, NCT00425672

Phase II Study of Dexamethasone Followed By Denileukin Diftitox in Patients With Persistent or Recurrent Cutaneous T-Cell Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LIGAND-L4389-MR-9901, NCI-V00-1614, NCT00006345

Phase II Study of Denileukin Diftitox in Patients With Stages I-IV Low- or Intermediate-Grade B-Cell Non-Hodgkin's Lymphoma (Summary Last Modified 02/2002). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PHARMATECH-LP-ONT-BL, LIGAND-PHARMATECH-LP-ONT-BL, PHARMATECH-20002024, NCT00026429

Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: L4389-34, NCT00055146

Phase II Study of Denileukin Diftitox in Patients With Metastatic Melanoma or Metastatic Kidney Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0134, NCT00082914

Phase II Study of Denileukin Diftitox in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CCCWFU-27102, CCCWFU-BG02-331, LIGAND-CCCWFU-27102, NCT00082940

10.

Phase II Study of Denileukin Diftitox in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0412087-01, LIGAND-PIND-123, NCT00138164

11.

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: #35, NCT00211185

12.

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: #123, NCT00211276

13.

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 050185, 05-C-0185, NCT00117845

14.

Phase II Trial of Ontak With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 076.06, NCT00299689

15.

Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000539551, NCCTG-N0682, N0682, NCT00460109

16.

Treatment for Acute Graft-Versus-Host Disease

Phase: Phase II
Type: Supportive care
Status: Completed
Age: 10 and over
Sponsor: NCI, NHLBI
Protocol IDs: 285, BMT CTN 0302, U01 HL069294-05, JHOC-05040403, JHOC-J0519, NCT00224874

17.

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 15232B, NCT00515528

18.

Treatment of Peripheral T-cell Lymphoma With Aggressive Induction Chemotherapy Followed by Autologous Stem Cell Transplant Using Denileukin Diftitox (Ontak)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: UC-PTCL-ONTAK, NCT00632827

19.

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066692, E1497, NCT00003615

20.

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 2 and over
Sponsor: Other
Protocol IDs: 2010LS010, MT2010-02, 1003M79954, NCT01106950

21.

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000437795, DUMC-NCI-7042, NCI-7042, 7042, NCT00128622

22.

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6193, NCI-2010-00832, UWCC-6193, UWCC-03-9836-D01, FHCRC-6193, FHCRC-UW-6193, FHCRC-119, NCT00357448

23.

Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 6223, NCI-2009-01547, FHCRC-6223, UWCC-UW 6223, UWCC- 03-7469-D 01, UWCC-UW03011, FHCRC-6223p, NCT00228358

24.

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: WSU 2010-039, NCT01251952

25.

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NU 04U1, P30CA060553, STU00006770, NCT00278369

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map